董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Chamath Palihapitiya | 男 | Chief Executive Officer and Chairman of the Board | 44 | 未披露 | 未持股 | 2021-06-29 |
| Marc Semigran | 男 | Director | 64 | 未披露 | 未持股 | 2021-06-29 |
| Kishan Mehta | 男 | President and Director | 35 | 未披露 | 未持股 | 2021-06-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Chamath Palihapitiya | 男 | Chief Executive Officer and Chairman of the Board | 44 | 未披露 | 未持股 | 2021-06-29 |
| James Ryans | 男 | Chief Financial Officer | 45 | 未披露 | 未持股 | 2021-06-29 |
| Kishan Mehta | 男 | President and Director | 35 | 未披露 | 未持股 | 2021-06-29 |
| Shoney Katz | 男 | Director of Research | 46 | 未披露 | 未持股 | 2021-06-29 |
董事简历
中英对照 | 中文 | 英文- Chamath Palihapitiya
-
Chamath Palihapitiya自2017年5月以来一直担任我们的首席执行官兼董事会主席。Palihapitiya先生是Social Capital的创始人和现任执行合伙人。在2011年创立Social Capital之前，Palihapitiya先生曾担任Facebook用户增长的Vice President，并被公认为Facebook推出和增长的主要力量。Palihapitiya先生负责监管货币化产品和Facebook平台，这两个都是推动Facebook用户群增至全球超过7.5亿人的关键因素。任职Facebook公司之前，Palihapitiya曾担任Mayfield Fund（美国最古老的风险投资公司之一）的负责人，此前他曾领导AOL公司的即时消息部门。Palihapitiya先生毕业于加拿大滑铁卢大学（University of Waterloo），获得电气工程学位。
Chamath Palihapitiya has been the Chairman of board of directors since July 2025. Mr. Palihapitiya is the founder and Managing Partner of Social Capital. Social Capital is a Silicon Valley based technology holding company founded by Mr. Palihapitiya in 2011 with a mission to advance humanity by solving the world's hardest problems. Social Capital invests across the company lifecycle, from early stage startups to transformational public companies. The platform is oriented toward long term ownership and has a strong investment track record and experience in driving dramatic growth. Social Capital foces on investing in fast growing companies creating significant disruption in multiple indtries including healthcare, space, financial services, artificial intelligence and social media. Alongside his work at Social Capital, Mr. Palihapitiya also founded 8090 in 2024. 8090's goal is to build an AI enabled software factory designed to produce high quality, ll maintained enterprise software and replace the trillions of lines of legacy software running inside of companies. Prior to founding Social Capital, Mr. Palihapitiya served as Vice President of er Growth at Facebook and is recognized as having been a major force in its launch and growth. Mr. Palihapitiya was responsible for overseeing Monetization Products and Facebook Platform, both of which re key factors driving the increase in Facebook's er base to more than 750 million individuals worldwide. Prior to working for Facebook, Mr. Palihapitiya was a principal at the Mayfield Fund, one of the United States' oldest venture firms, before which he headed the instant messaging division at AOL. - Chamath Palihapitiya自2017年5月以来一直担任我们的首席执行官兼董事会主席。Palihapitiya先生是Social Capital的创始人和现任执行合伙人。在2011年创立Social Capital之前，Palihapitiya先生曾担任Facebook用户增长的Vice President，并被公认为Facebook推出和增长的主要力量。Palihapitiya先生负责监管货币化产品和Facebook平台，这两个都是推动Facebook用户群增至全球超过7.5亿人的关键因素。任职Facebook公司之前，Palihapitiya曾担任Mayfield Fund（美国最古老的风险投资公司之一）的负责人，此前他曾领导AOL公司的即时消息部门。Palihapitiya先生毕业于加拿大滑铁卢大学（University of Waterloo），获得电气工程学位。
- Chamath Palihapitiya has been the Chairman of board of directors since July 2025. Mr. Palihapitiya is the founder and Managing Partner of Social Capital. Social Capital is a Silicon Valley based technology holding company founded by Mr. Palihapitiya in 2011 with a mission to advance humanity by solving the world's hardest problems. Social Capital invests across the company lifecycle, from early stage startups to transformational public companies. The platform is oriented toward long term ownership and has a strong investment track record and experience in driving dramatic growth. Social Capital foces on investing in fast growing companies creating significant disruption in multiple indtries including healthcare, space, financial services, artificial intelligence and social media. Alongside his work at Social Capital, Mr. Palihapitiya also founded 8090 in 2024. 8090's goal is to build an AI enabled software factory designed to produce high quality, ll maintained enterprise software and replace the trillions of lines of legacy software running inside of companies. Prior to founding Social Capital, Mr. Palihapitiya served as Vice President of er Growth at Facebook and is recognized as having been a major force in its launch and growth. Mr. Palihapitiya was responsible for overseeing Monetization Products and Facebook Platform, both of which re key factors driving the increase in Facebook's er base to more than 750 million individuals worldwide. Prior to working for Facebook, Mr. Palihapitiya was a principal at the Mayfield Fund, one of the United States' oldest venture firms, before which he headed the instant messaging division at AOL.
- Marc Semigran
-
Marc Semigran自2016年12月起担任我们的首席医疗官。他曾担任the Massachusetts General Hospital Heart Fault and Cardiac Transplant Program的医学董事（从2004年4月到2016年11月），在那里他负责心力衰竭患者护理的总体方向，包括那些需要或已经接受心脏移植的患者。Semigran博士还从2010年1月至今担任哈佛医学院（Harvard Medical School）的医学副教授。他是the Harvard/MIT Health Sciences and Technology Program的毕业生，并在Massachusetts General Hospital完成内科住院医师和心脏病学研究金培训。Semigran博士拥有哈佛医学院（Harvard Medical School）的医学博士学位，并持有哈佛大学（Harvard University）化学AB和AM学位。
Marc Semigran will serve as a director following the completion of this offering. In June 2021 Dr. Semigran was appointed as chief medical officer of Renovacor, Inc., an early-stage biotechnology company focused on the development of therapies for cardiovascular and central nervous system diseases. Prior to joining Renovacor, Dr. Semigran was an Associate Professor of Medicine at Harvard Medical School, a position he held from January 2010-February 2017. He previously served as Chief Medical Officer of MyoKardia from December 2016 until the acquisition of MyoKardia by Bristol-Myers Squibb in 2020 for approximately $13.1 billion. Prior to MyoKardia, from April 2004 through February 2017 Dr. Semigran served as Medical Director of the Massachusetts General Hospital Heart Failure and Cardiac Transplant Program, where he was responsible for leading the overall direction of the care of heart failure patients, including with respect to cardiac transplantation. He is an active investigator in translational and clinical medicine as applied to heart failure and cardiomyopathy. His research was funded by NIH and other peer-reviewed grants, and continues with industry funding. Dr Semigran is a graduate of the Harvard/MIT Health Sciences and Technology Program and completed his internal medicine residency and cardiology fellowship training at Massachusetts General Hospital. Dr. Semigran holds an M.D. from Harvard Medical School and an AB/AM in chemistry from Harvard University. - Marc Semigran自2016年12月起担任我们的首席医疗官。他曾担任the Massachusetts General Hospital Heart Fault and Cardiac Transplant Program的医学董事（从2004年4月到2016年11月），在那里他负责心力衰竭患者护理的总体方向，包括那些需要或已经接受心脏移植的患者。Semigran博士还从2010年1月至今担任哈佛医学院（Harvard Medical School）的医学副教授。他是the Harvard/MIT Health Sciences and Technology Program的毕业生，并在Massachusetts General Hospital完成内科住院医师和心脏病学研究金培训。Semigran博士拥有哈佛医学院（Harvard Medical School）的医学博士学位，并持有哈佛大学（Harvard University）化学AB和AM学位。
- Marc Semigran will serve as a director following the completion of this offering. In June 2021 Dr. Semigran was appointed as chief medical officer of Renovacor, Inc., an early-stage biotechnology company focused on the development of therapies for cardiovascular and central nervous system diseases. Prior to joining Renovacor, Dr. Semigran was an Associate Professor of Medicine at Harvard Medical School, a position he held from January 2010-February 2017. He previously served as Chief Medical Officer of MyoKardia from December 2016 until the acquisition of MyoKardia by Bristol-Myers Squibb in 2020 for approximately $13.1 billion. Prior to MyoKardia, from April 2004 through February 2017 Dr. Semigran served as Medical Director of the Massachusetts General Hospital Heart Failure and Cardiac Transplant Program, where he was responsible for leading the overall direction of the care of heart failure patients, including with respect to cardiac transplantation. He is an active investigator in translational and clinical medicine as applied to heart failure and cardiomyopathy. His research was funded by NIH and other peer-reviewed grants, and continues with industry funding. Dr Semigran is a graduate of the Harvard/MIT Health Sciences and Technology Program and completed his internal medicine residency and cardiology fellowship training at Massachusetts General Hospital. Dr. Semigran holds an M.D. from Harvard Medical School and an AB/AM in chemistry from Harvard University.
- Kishan Mehta
-
自2021年2月以来，Kishan Mehta一直担任我们的总裁兼董事会成员。Mehta先生还担任DNAA，DNAB和DNAD的总裁兼董事会成员。Mehta先生还担任Biohaven Pharmaceuticals NYSE:BHVN的董事会成员。在加入Suvretta担任Averill Strategy的投资组合经理之前，Mehta先生曾担任Biohaven的战略顾问，在那里，他为公司的各种业务发展，资本结构和沟通策略提供建议，包括3亿美元的二次公开募股和1.05亿美元从Gw Pharmaceuticals Plc购买的优先审查凭证，其中包括从Royalty Pharma plc获得的2亿美元融资，以资助交易。任职Biohaven公司之前，他曾担任Surveyor Capital公司（城堡有限责任公司的战略）的投资组合经理，在那里他曾管理投资组合，专注于全球小型、中型和大型资本生物技术、制药、专业制药、医疗设备和医疗保健服务。任职Surveyor公司之前，他曾担任Adage Capital公司的分析师，在那里他曾评估和参与多种夹层和上市前私人医疗保健投资。Mehta先生在Apothecary Capital担任过类似的职务，并在Evercore Partners担任并购分析师开始了他的职业生涯，在那里他专注于生命科学。Mehta先生毕业于纽约大学，获得财务和会计学位。
Kishan Mehta has been our President and a member of our board of directors since February 2021. Mr. Mehta also serves as the President and a member of the board of directors of DNAA, DNAB and DNAD. Mr. Mehta also serves as a member of the board of directors of Biohaven Pharmaceuticals NYSE: BHVN. Prior to joining Suvretta as Portfolio Manager for the Averill strategy, Mr. Mehta served as a strategic advisor to Biohaven, where he advised the company on various business development, capital structure and communication strategies, including a $300 million secondary public offering and the $105 million purchase of a Priority Review Voucher from GW Pharmaceuticals plc, which included $200 million in financing from Royalty Pharma plc to fund the transaction. Prior to his advisory role at Biohaven, Mr. Mehta was a portfolio manager at Surveyor Capital, a Citadel LLC strategy, where he managed a portfolio focused on global small-, mid- and large-capitalization biotechnology, pharmaceutical, specialty pharmaceutical, medical device and healthcare services. Prior to Surveyor, Mr. Mehta was an analyst at Adage Capital where he evaluated and participated in numerous mezzanine and pre-IPO private healthcare investments. Mr. Mehta held a similar role at Apothecary Capital and started his career as a mergers and acquisitions analyst at Evercore Partners, where he focused on life sciences. Mr. Mehta graduated from New York University with a degree in finance and accounting. - 自2021年2月以来，Kishan Mehta一直担任我们的总裁兼董事会成员。Mehta先生还担任DNAA，DNAB和DNAD的总裁兼董事会成员。Mehta先生还担任Biohaven Pharmaceuticals NYSE:BHVN的董事会成员。在加入Suvretta担任Averill Strategy的投资组合经理之前，Mehta先生曾担任Biohaven的战略顾问，在那里，他为公司的各种业务发展，资本结构和沟通策略提供建议，包括3亿美元的二次公开募股和1.05亿美元从Gw Pharmaceuticals Plc购买的优先审查凭证，其中包括从Royalty Pharma plc获得的2亿美元融资，以资助交易。任职Biohaven公司之前，他曾担任Surveyor Capital公司（城堡有限责任公司的战略）的投资组合经理，在那里他曾管理投资组合，专注于全球小型、中型和大型资本生物技术、制药、专业制药、医疗设备和医疗保健服务。任职Surveyor公司之前，他曾担任Adage Capital公司的分析师，在那里他曾评估和参与多种夹层和上市前私人医疗保健投资。Mehta先生在Apothecary Capital担任过类似的职务，并在Evercore Partners担任并购分析师开始了他的职业生涯，在那里他专注于生命科学。Mehta先生毕业于纽约大学，获得财务和会计学位。
- Kishan Mehta has been our President and a member of our board of directors since February 2021. Mr. Mehta also serves as the President and a member of the board of directors of DNAA, DNAB and DNAD. Mr. Mehta also serves as a member of the board of directors of Biohaven Pharmaceuticals NYSE: BHVN. Prior to joining Suvretta as Portfolio Manager for the Averill strategy, Mr. Mehta served as a strategic advisor to Biohaven, where he advised the company on various business development, capital structure and communication strategies, including a $300 million secondary public offering and the $105 million purchase of a Priority Review Voucher from GW Pharmaceuticals plc, which included $200 million in financing from Royalty Pharma plc to fund the transaction. Prior to his advisory role at Biohaven, Mr. Mehta was a portfolio manager at Surveyor Capital, a Citadel LLC strategy, where he managed a portfolio focused on global small-, mid- and large-capitalization biotechnology, pharmaceutical, specialty pharmaceutical, medical device and healthcare services. Prior to Surveyor, Mr. Mehta was an analyst at Adage Capital where he evaluated and participated in numerous mezzanine and pre-IPO private healthcare investments. Mr. Mehta held a similar role at Apothecary Capital and started his career as a mergers and acquisitions analyst at Evercore Partners, where he focused on life sciences. Mr. Mehta graduated from New York University with a degree in finance and accounting.
高管简历
中英对照 | 中文 | 英文- Chamath Palihapitiya
Chamath Palihapitiya自2017年5月以来一直担任我们的首席执行官兼董事会主席。Palihapitiya先生是Social Capital的创始人和现任执行合伙人。在2011年创立Social Capital之前，Palihapitiya先生曾担任Facebook用户增长的Vice President，并被公认为Facebook推出和增长的主要力量。Palihapitiya先生负责监管货币化产品和Facebook平台，这两个都是推动Facebook用户群增至全球超过7.5亿人的关键因素。任职Facebook公司之前，Palihapitiya曾担任Mayfield Fund（美国最古老的风险投资公司之一）的负责人，此前他曾领导AOL公司的即时消息部门。Palihapitiya先生毕业于加拿大滑铁卢大学（University of Waterloo），获得电气工程学位。
Chamath Palihapitiya has been the Chairman of board of directors since July 2025. Mr. Palihapitiya is the founder and Managing Partner of Social Capital. Social Capital is a Silicon Valley based technology holding company founded by Mr. Palihapitiya in 2011 with a mission to advance humanity by solving the world's hardest problems. Social Capital invests across the company lifecycle, from early stage startups to transformational public companies. The platform is oriented toward long term ownership and has a strong investment track record and experience in driving dramatic growth. Social Capital foces on investing in fast growing companies creating significant disruption in multiple indtries including healthcare, space, financial services, artificial intelligence and social media. Alongside his work at Social Capital, Mr. Palihapitiya also founded 8090 in 2024. 8090's goal is to build an AI enabled software factory designed to produce high quality, ll maintained enterprise software and replace the trillions of lines of legacy software running inside of companies. Prior to founding Social Capital, Mr. Palihapitiya served as Vice President of er Growth at Facebook and is recognized as having been a major force in its launch and growth. Mr. Palihapitiya was responsible for overseeing Monetization Products and Facebook Platform, both of which re key factors driving the increase in Facebook's er base to more than 750 million individuals worldwide. Prior to working for Facebook, Mr. Palihapitiya was a principal at the Mayfield Fund, one of the United States' oldest venture firms, before which he headed the instant messaging division at AOL.- Chamath Palihapitiya自2017年5月以来一直担任我们的首席执行官兼董事会主席。Palihapitiya先生是Social Capital的创始人和现任执行合伙人。在2011年创立Social Capital之前，Palihapitiya先生曾担任Facebook用户增长的Vice President，并被公认为Facebook推出和增长的主要力量。Palihapitiya先生负责监管货币化产品和Facebook平台，这两个都是推动Facebook用户群增至全球超过7.5亿人的关键因素。任职Facebook公司之前，Palihapitiya曾担任Mayfield Fund（美国最古老的风险投资公司之一）的负责人，此前他曾领导AOL公司的即时消息部门。Palihapitiya先生毕业于加拿大滑铁卢大学（University of Waterloo），获得电气工程学位。
- Chamath Palihapitiya has been the Chairman of board of directors since July 2025. Mr. Palihapitiya is the founder and Managing Partner of Social Capital. Social Capital is a Silicon Valley based technology holding company founded by Mr. Palihapitiya in 2011 with a mission to advance humanity by solving the world's hardest problems. Social Capital invests across the company lifecycle, from early stage startups to transformational public companies. The platform is oriented toward long term ownership and has a strong investment track record and experience in driving dramatic growth. Social Capital foces on investing in fast growing companies creating significant disruption in multiple indtries including healthcare, space, financial services, artificial intelligence and social media. Alongside his work at Social Capital, Mr. Palihapitiya also founded 8090 in 2024. 8090's goal is to build an AI enabled software factory designed to produce high quality, ll maintained enterprise software and replace the trillions of lines of legacy software running inside of companies. Prior to founding Social Capital, Mr. Palihapitiya served as Vice President of er Growth at Facebook and is recognized as having been a major force in its launch and growth. Mr. Palihapitiya was responsible for overseeing Monetization Products and Facebook Platform, both of which re key factors driving the increase in Facebook's er base to more than 750 million individuals worldwide. Prior to working for Facebook, Mr. Palihapitiya was a principal at the Mayfield Fund, one of the United States' oldest venture firms, before which he headed the instant messaging division at AOL.
- James Ryans
James Ryans自2016年以来一直担任伦敦商学院（London Business School）会计学教授。从2012年7月至2016年5月，Ryans博士担任加州大学伯克利分校的会计讲师，同时进行博士学习。Ryans从2003年6月到2011年6月担任Chelsea Rhone LLC及其附属公司HealthCap RRG（一家共同保险公司，为长期护理行业提供商业责任保险）多个高级管理职位，最近担任投资主管。从1999年8月到2001年6月，Ryans博士担任德勤会计师事务所（Deloitte&Touche）的顾问和高级顾问。Ryans博士目前在Groundspeed Analytics，Inc.（一家保险数据分析提供商）的董事会任职。Ryans博士是CFA特许持有人，并持有加州大学伯克利分校工商管理会计博士学位，密歇根大学工商管理硕士学位和工商管理硕士学位。滑铁卢大学电气工程学士学位。
James Ryans has been our Chief Financial Officer since February 2021. Mr. Ryans also serves as the Chief Financial Officer of DNAA, DNAB, DNAD, Social Capital Hedosophia Holdings Corp. IV and Social Capital Hedosophia Holdings Corp. VI. Mr. Ryans is a Partner at Social Capital since March 2021 and has been a professor of accounting at London Business School since 2016 teaching financial accounting at the graduate and postgraduate levels, and directs an executive education program on mergers and acquisitions. Mr. Ryans previously served as a member of the board of directors of Social Capital Hedosophia Holdings Corp. III from April 2020 until the consummation of its business combination with Clover Health Investments, Corp. in January 2021 as a director and the chairman of the audit committee of Social Capital Hedosophia Holdings Corp. from September 2017 until the consummation of its business combination with Virgin Galactic in October 2019 and as a member of Virgin Galactic’s board of directors through February 2021. From 2003 to 2011 Mr. Ryans oversaw investments and business development at Chelsea Rhone LLC and its affiliate HealthCap RRG, a mutual insurance company. From 1999 until 2001 Mr. Ryans was a consultant with Deloitte & Touche. Mr. Ryans is a CFA charterholder and holds a Ph.D. in business administration from the University of California Berkeley, an MBA from the University of Michigan and a BASc in electrical engineering from the University of Waterloo.- James Ryans自2016年以来一直担任伦敦商学院（London Business School）会计学教授。从2012年7月至2016年5月，Ryans博士担任加州大学伯克利分校的会计讲师，同时进行博士学习。Ryans从2003年6月到2011年6月担任Chelsea Rhone LLC及其附属公司HealthCap RRG（一家共同保险公司，为长期护理行业提供商业责任保险）多个高级管理职位，最近担任投资主管。从1999年8月到2001年6月，Ryans博士担任德勤会计师事务所（Deloitte&Touche）的顾问和高级顾问。Ryans博士目前在Groundspeed Analytics，Inc.（一家保险数据分析提供商）的董事会任职。Ryans博士是CFA特许持有人，并持有加州大学伯克利分校工商管理会计博士学位，密歇根大学工商管理硕士学位和工商管理硕士学位。滑铁卢大学电气工程学士学位。
- James Ryans has been our Chief Financial Officer since February 2021. Mr. Ryans also serves as the Chief Financial Officer of DNAA, DNAB, DNAD, Social Capital Hedosophia Holdings Corp. IV and Social Capital Hedosophia Holdings Corp. VI. Mr. Ryans is a Partner at Social Capital since March 2021 and has been a professor of accounting at London Business School since 2016 teaching financial accounting at the graduate and postgraduate levels, and directs an executive education program on mergers and acquisitions. Mr. Ryans previously served as a member of the board of directors of Social Capital Hedosophia Holdings Corp. III from April 2020 until the consummation of its business combination with Clover Health Investments, Corp. in January 2021 as a director and the chairman of the audit committee of Social Capital Hedosophia Holdings Corp. from September 2017 until the consummation of its business combination with Virgin Galactic in October 2019 and as a member of Virgin Galactic’s board of directors through February 2021. From 2003 to 2011 Mr. Ryans oversaw investments and business development at Chelsea Rhone LLC and its affiliate HealthCap RRG, a mutual insurance company. From 1999 until 2001 Mr. Ryans was a consultant with Deloitte & Touche. Mr. Ryans is a CFA charterholder and holds a Ph.D. in business administration from the University of California Berkeley, an MBA from the University of Michigan and a BASc in electrical engineering from the University of Waterloo.
- Kishan Mehta
自2021年2月以来，Kishan Mehta一直担任我们的总裁兼董事会成员。Mehta先生还担任DNAA，DNAB和DNAD的总裁兼董事会成员。Mehta先生还担任Biohaven Pharmaceuticals NYSE:BHVN的董事会成员。在加入Suvretta担任Averill Strategy的投资组合经理之前，Mehta先生曾担任Biohaven的战略顾问，在那里，他为公司的各种业务发展，资本结构和沟通策略提供建议，包括3亿美元的二次公开募股和1.05亿美元从Gw Pharmaceuticals Plc购买的优先审查凭证，其中包括从Royalty Pharma plc获得的2亿美元融资，以资助交易。任职Biohaven公司之前，他曾担任Surveyor Capital公司（城堡有限责任公司的战略）的投资组合经理，在那里他曾管理投资组合，专注于全球小型、中型和大型资本生物技术、制药、专业制药、医疗设备和医疗保健服务。任职Surveyor公司之前，他曾担任Adage Capital公司的分析师，在那里他曾评估和参与多种夹层和上市前私人医疗保健投资。Mehta先生在Apothecary Capital担任过类似的职务，并在Evercore Partners担任并购分析师开始了他的职业生涯，在那里他专注于生命科学。Mehta先生毕业于纽约大学，获得财务和会计学位。
Kishan Mehta has been our President and a member of our board of directors since February 2021. Mr. Mehta also serves as the President and a member of the board of directors of DNAA, DNAB and DNAD. Mr. Mehta also serves as a member of the board of directors of Biohaven Pharmaceuticals NYSE: BHVN. Prior to joining Suvretta as Portfolio Manager for the Averill strategy, Mr. Mehta served as a strategic advisor to Biohaven, where he advised the company on various business development, capital structure and communication strategies, including a $300 million secondary public offering and the $105 million purchase of a Priority Review Voucher from GW Pharmaceuticals plc, which included $200 million in financing from Royalty Pharma plc to fund the transaction. Prior to his advisory role at Biohaven, Mr. Mehta was a portfolio manager at Surveyor Capital, a Citadel LLC strategy, where he managed a portfolio focused on global small-, mid- and large-capitalization biotechnology, pharmaceutical, specialty pharmaceutical, medical device and healthcare services. Prior to Surveyor, Mr. Mehta was an analyst at Adage Capital where he evaluated and participated in numerous mezzanine and pre-IPO private healthcare investments. Mr. Mehta held a similar role at Apothecary Capital and started his career as a mergers and acquisitions analyst at Evercore Partners, where he focused on life sciences. Mr. Mehta graduated from New York University with a degree in finance and accounting.- 自2021年2月以来，Kishan Mehta一直担任我们的总裁兼董事会成员。Mehta先生还担任DNAA，DNAB和DNAD的总裁兼董事会成员。Mehta先生还担任Biohaven Pharmaceuticals NYSE:BHVN的董事会成员。在加入Suvretta担任Averill Strategy的投资组合经理之前，Mehta先生曾担任Biohaven的战略顾问，在那里，他为公司的各种业务发展，资本结构和沟通策略提供建议，包括3亿美元的二次公开募股和1.05亿美元从Gw Pharmaceuticals Plc购买的优先审查凭证，其中包括从Royalty Pharma plc获得的2亿美元融资，以资助交易。任职Biohaven公司之前，他曾担任Surveyor Capital公司（城堡有限责任公司的战略）的投资组合经理，在那里他曾管理投资组合，专注于全球小型、中型和大型资本生物技术、制药、专业制药、医疗设备和医疗保健服务。任职Surveyor公司之前，他曾担任Adage Capital公司的分析师，在那里他曾评估和参与多种夹层和上市前私人医疗保健投资。Mehta先生在Apothecary Capital担任过类似的职务，并在Evercore Partners担任并购分析师开始了他的职业生涯，在那里他专注于生命科学。Mehta先生毕业于纽约大学，获得财务和会计学位。
- Kishan Mehta has been our President and a member of our board of directors since February 2021. Mr. Mehta also serves as the President and a member of the board of directors of DNAA, DNAB and DNAD. Mr. Mehta also serves as a member of the board of directors of Biohaven Pharmaceuticals NYSE: BHVN. Prior to joining Suvretta as Portfolio Manager for the Averill strategy, Mr. Mehta served as a strategic advisor to Biohaven, where he advised the company on various business development, capital structure and communication strategies, including a $300 million secondary public offering and the $105 million purchase of a Priority Review Voucher from GW Pharmaceuticals plc, which included $200 million in financing from Royalty Pharma plc to fund the transaction. Prior to his advisory role at Biohaven, Mr. Mehta was a portfolio manager at Surveyor Capital, a Citadel LLC strategy, where he managed a portfolio focused on global small-, mid- and large-capitalization biotechnology, pharmaceutical, specialty pharmaceutical, medical device and healthcare services. Prior to Surveyor, Mr. Mehta was an analyst at Adage Capital where he evaluated and participated in numerous mezzanine and pre-IPO private healthcare investments. Mr. Mehta held a similar role at Apothecary Capital and started his career as a mergers and acquisitions analyst at Evercore Partners, where he focused on life sciences. Mr. Mehta graduated from New York University with a degree in finance and accounting.
- Shoney Katz
Shoney Katz自2021年2月起担任我们的研究总监。Katz先生还担任DNAA，DNAB和DNAD的研究总监。Katz先生是Suvretta的董事总经理兼高级分析师，在公共和私人市场投资方面拥有丰富的经验。在加入Suvretta之前，Katz先生曾在Citadel LLC&8217；S Surveyor Capital担任投资组合经理，在那里他管理着与工业，消费者和金融相关的想法的投资组合。从2008年到2014年，Katz先生在Point72Asset Management担任高级分析师，专注于各个行业的基础和机会主义想法。Katz先生还曾在私募股权公司（包括凯雷集团和AEA Investors）担任职务，并在贝恩公司（Bain&Company）担任分析师的管理咨询职位。Katz先生拥有哈佛商学院的工商管理硕士学位，以及莱斯大学的机械工程学士学位和经济学学士学位。
Shoney Katz has been our Director of Research since February 2021. Mr. Katz also serves as the Director of Research of DNAA, DNAB and DNAD. Mr. Katz is a Managing Director and Senior Analyst at Suvretta, with extensive experience investing in public and private markets. Prior to joining Suvretta, Mr. Katz worked as a Portfolio Manager at Citadel LLC’s Surveyor Capital, where he managed a portfolio of industrial, consumer and financial-related ideas. From 2008 to 2014 Mr. Katz worked as a Senior Analyst at Point72 Asset Management, focused on fundamental and opportunistic ideas across various sectors. Mr. Katz also previously held positions at private equity firms, including The Carlyle Group and AEA Investors, and in management consulting as an analyst at Bain & Company. Mr. Katz holds an MBA from Harvard Business School and a Bachelor of Science in Mechanical Engineering and a Bachelor of Arts in Economics from Rice University.- Shoney Katz自2021年2月起担任我们的研究总监。Katz先生还担任DNAA，DNAB和DNAD的研究总监。Katz先生是Suvretta的董事总经理兼高级分析师，在公共和私人市场投资方面拥有丰富的经验。在加入Suvretta之前，Katz先生曾在Citadel LLC&8217；S Surveyor Capital担任投资组合经理，在那里他管理着与工业，消费者和金融相关的想法的投资组合。从2008年到2014年，Katz先生在Point72Asset Management担任高级分析师，专注于各个行业的基础和机会主义想法。Katz先生还曾在私募股权公司（包括凯雷集团和AEA Investors）担任职务，并在贝恩公司（Bain&Company）担任分析师的管理咨询职位。Katz先生拥有哈佛商学院的工商管理硕士学位，以及莱斯大学的机械工程学士学位和经济学学士学位。
- Shoney Katz has been our Director of Research since February 2021. Mr. Katz also serves as the Director of Research of DNAA, DNAB and DNAD. Mr. Katz is a Managing Director and Senior Analyst at Suvretta, with extensive experience investing in public and private markets. Prior to joining Suvretta, Mr. Katz worked as a Portfolio Manager at Citadel LLC’s Surveyor Capital, where he managed a portfolio of industrial, consumer and financial-related ideas. From 2008 to 2014 Mr. Katz worked as a Senior Analyst at Point72 Asset Management, focused on fundamental and opportunistic ideas across various sectors. Mr. Katz also previously held positions at private equity firms, including The Carlyle Group and AEA Investors, and in management consulting as an analyst at Bain & Company. Mr. Katz holds an MBA from Harvard Business School and a Bachelor of Science in Mechanical Engineering and a Bachelor of Arts in Economics from Rice University.